Home Insights Investment Biotech: The Ultimate Impact Investment? | TIGER 21 Chair Featured in Financial Times

Biotech: The Ultimate Impact Investment? | TIGER 21 Chair Featured in Financial Times

Author

TIGER 21

Published On

June 8, 2023

Published In

Philanthropy, Chair Insights, Member Insights, Investment

Share on Social

Orlando TIGER 21 Chair Eric Casaburi was recently featured in the Financial Times, where he shared his insights on how the ultra-high-net-worth community is currently approaching biotech investing and the tremendous movement into the healthcare space. A survey of TIGER 21 Members found that nearly 25% planned to invest in healthcare this year.

The emphasis on healthcare is reflected in the flow of family office money into venture capital. Despite the potential risk if a treatment does not work, the rewards in healthcare can be substantial, making it an impact investment.

Read the article here.

About TIGER 21

TIGER 21 is an exclusive global community of ultra-high-net-worth entrepreneurs, investors, and executives.

Explore the TIGER 21 Member Experience

Member Insight Reports

Download the Asset Allocation Report to see the latest Member portfolio data.

Download Report

Life After Selling a Business: What to expect, what you might not expect, and what’s next.

View the Report

Get TIGER 21 Insights in Your Inbox Monthly*
First Last
Email*
By submitting this form, you consent to receive marketing emails from TIGER 21 relating to content and events that may be of interest to you. You may unsubscribe at any time by following the instructions listed in any marketing email you receive from TIGER 21.
Name
This field is for validation purposes and should be left unchanged.